Regeneron Pharmaceuticals, Inc. Stock price
Equities
REGN
US75886F1075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
835.75 USD | +1.81% | +3.36% | +15.84% |
Financials (USD)
Sales 2023 * | 12.93B | Sales 2024 * | 13.51B | Capitalization | 88.88B |
---|---|---|---|---|---|
Net income 2023 * | 3.82B | Net income 2024 * | 4.29B | EV / Sales 2023 * | 6,37x |
Net cash position 2023 * | 6.46B | Net cash position 2024 * | 10.66B | EV / Sales 2024 * | 5,79x |
P/E ratio 2023 * | 24,6x | P/E ratio 2024 * | 22,1x | Employees | 12,463 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 77.88% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +1.81% | ||
1 week | +3.36% | ||
Current month | +1.45% | ||
1 month | +0.40% | ||
3 months | +2.12% | ||
6 months | +11.71% | ||
Current year | +15.84% |
1 week
802.55
842.00

1 month
783.57
842.00

Current year
668.00
853.97

1 year
668.00
853.97

3 years
441.00
853.97

5 years
271.37
853.97

10 years
257.69
853.97

Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 1988 | |
Chairman | 63 | 1989 | |
Robert Landry
DFI | Director of Finance/CFO | 59 | 2013 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christine Poon
BRD | Director/Board Member | 70 | 2010 |
Chief Executive Officer | 70 | 1988 | |
Michael S. Brown
BRD | Director/Board Member | 81 | 1991 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.32% | 5 M€ | -16.24% | ||
8.44% | 329 M€ | -8.41% | ||
8.44% | 34 M€ | -3.97% | - | |
8.40% | 15 M€ | -5.31% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-06 | 835.75 | +1.81% | 554,087 |
23-12-05 | 820.9 | -0.29% | 319,428 |
23-12-04 | 823.32 | +1.04% | 508,434 |
23-12-01 | 814.86 | -1.09% | 560,248 |
23-11-30 | 823.81 | +1.88% | 954,624 |
Delayed Quote Nasdaq, December 06, 2023 at 04:00 pm EST
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
835.75USD
Average target price
912.57USD
Spread / Average Target
+9.19%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.84% | 88 879 M $ | |
+22.40% | 91 081 M $ | |
-5.98% | 31 581 M $ | |
+22.25% | 27 228 M $ | |
-32.54% | 24 090 M $ | |
-24.92% | 21 026 M $ | |
-17.26% | 18 954 M $ | |
+0.03% | 11 738 M $ | |
+22.68% | 11 133 M $ | |
-32.57% | 8 174 M $ |